Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06865571 administered Day 7-14 · 1 trial · 1 indication
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 12 hours.
Maximum observed concentration from Time Zero to End if Dosing Interval (Cmax)
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 12 hours.
Maximum observed concentration from Time Zero to End if Dosing Interval (Cmax)
| Arm | Type | Description |
|---|---|---|
| Effect of PF-05221304 on PF-06865571 PK | EXPERIMENTAL | - |
| Effect of PF-06865571 on PF-05221304 PK | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-06865571 administered Day 7-14 | DRUG | PF-06865571 administered Q12hr on Days 7-14 |
| PF-06865571 administered Day 1-14 | DRUG | PF-06865571 administered Q12hr on Day 7-14 |
| PF-05221304 administered Day 1-14 | DRUG | PF-05221304 administered Q12hr on Days 1-14 |
| PF-05221304 administered Day 7-14 | DRUG | PF-05221304 administered Q12hr Days 7-14 |
Inclusion criteria: 1. Healthy female subjects of nonchildbearing potential and/or male subjects. 2. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). Exclusion Criteria 1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonar...
PF-06865571 is an investigational small molecule being studied in healthy adult subjects. It is being evaluated in a Phase 1 clinical trial to assess its pharmacokinetic drug-drug interaction with another Pfizer compound, PF-05221304. The drug is not approved and remains in clinical development.
PF-06865571 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting a Phase 1 clinical trial to evaluate the drug's pharmacokinetic interactions in healthy volunteers.
PF-06865571 is in Phase 1 clinical development. It is an investigational drug that has not been approved by regulatory authorities. The single Phase 1 trial studying this drug has been completed, and it remains in early-stage clinical research.
PF-06865571 has been studied in one completed Phase 1 clinical trial, identified as NCT03534648. This trial evaluated the pharmacokinetic drug-drug interaction between PF-06865571 and PF-05221304 in healthy adult subjects. The study enrolled 16 participants and was conducted in Belgium.
No, PF-06865571 is not the same as PF-05221304. These are two distinct investigational compounds developed by Pfizer. The clinical trial NCT03534648 was designed to evaluate the pharmacokinetic drug-drug interaction between these two separate drugs when administered together in healthy subjects.